Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Recruiting
Observational Study
Metastatic Castration Resistant Prostate Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Male
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All patients must meet the following inclusion criteria during the identification period:
* Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed be…
Contacts
Novartis Pharmaceuticals
CONTACT